No Data
No Data
No Data
No Data
No Data
Should You Investigate RxSight, Inc. (NASDAQ:RXST) At US$52.84?
Yahoo FinanceApr 26 00:19
RxSight, Inc. to Report First Quarter Financial Results on May 6, 2024
ALISO VIEJO, Calif., April 22, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery,
GlobeNewswireApr 23 04:05
Companies Like RxSight (NASDAQ:RXST) Can Afford To Invest In Growth
We can readily understand why investors are attracted to unprofitable companies. Indeed, RxSight (NASDAQ:RXST) stock is up 197% in the last year, providing strong gains for shareholders. But while
Simply Wall StApr 19 19:14
Needham Sees BSX, CNMD, RMD Beating Street, Despite Medtech Slow Down
Seeking AlphaApr 15 05:56
Assessing RxSight: Insights From 8 Financial Analysts
RxSight (NASDAQ:RXST) underwent analysis by 8 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.Summarizing their recent assessments, the table below illustrates
BenzingaApr 11 20:00
Needham: Reiterated the RxSight (RXST.US) rating, adjusted from buy to buy rating, target price $64.00.
Needham: Reiterated the RxSight (RXST.US) rating, adjusted from buy to buy rating, target price $64.00.
Zhitong FinanceApr 11 18:01
No Data
No Data